(1S,4S)-2-Methyl-2,5-diazabicyclo(2.2.2)octane | 1260617-56-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 英文名称: (1S,4S)-2-Methyl-2,5-diazabicyclo(2.2.2)octane
• 英文别名: (1S,4S)-2-methyl-2,5-diazabicyclo[2.2.2]octane
• CAS: 1260617-56-8
• 化学式: C₇H₁₄N₂
• 分子量: 126.202
• InChiKey: GXIMUJOQZCMEFY-BQBZGAKWSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.2
• 重原子数：
  9
• 可旋转键数：
  0
• 环数：
  3.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  15.3
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  8-bromo-2-(chloromethyl)benzofuro[3,2-d]pyrimidin-4(3H)-one 、 (1S,4S)-2-Methyl-2,5-diazabicyclo(2.2.2)octane 以 乙醇 为溶剂， 生成 8-bromo-2-[[(1S,4S)-5-methyl-2,5-diazabicyclo[2.2.2]octan-2-yl]methyl]-3H-[1]benzofuro[3,2-d]pyrimidin-4-one
  参考文献：
  名称：

  The design, synthesis, and biological evaluation of PIM kinase inhibitors

  摘要：

  A series of substituted benzofuropyrimidinones with pan-PIM activities and excellent selectivity against a panel of diverse kinases is described. Initial exploration identified aryl benzofuropyrimidinones that were potent, but had cell permeability limitation. Using X-ray crystal structures of the bound PIM-1 complexes with 3, 5m, and 6d, we were able to guide the SAR and identify the alkyl benzofuropyrimidinone (6l) with good PIM potencies, permeability, and oral exposure. (C) 2012 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2012.04.025

文献信息

• NOVEL 3-AMINOALKYL-1,3-DIHYDRO-2H-INDOL-2-ONE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF
  申请人：FOULON Loic

  公开号：US20110059955A1

  公开（公告）日：2011-03-10

  The present invention relates to novel 3-aminoalkyl-1,3-dihydro-2H-indol-2-one derivatives, to their preparation and to their therapeutic application. The compounds of the present invention correspond to the formula (I): in which the variables are as set forth in the specification. These compounds exhibit a strong affinity and a high selectivity for human arginine-vasopressin (AVP) V 1a receptors and some compounds additionally exhibit a strong affinity for AVP V 1b receptors.

  本发明涉及新颖的3-氨基烷基-1,3-二氢-2H-吲哚-2-酮衍生物，其制备以及其治疗应用。本发明的化合物对应于式(I)： 其中变量如规范中所述。这些化合物表现出对人类精氨酸加压素（AVP）V1a受体具有强亲和力和高选择性，而且一些化合物还表现出对AVP V1b受体具有强亲和力。
• [EN] A COMPOUND HAVING INHIBITORY ACTIVITY AGAINST KRAS G12D MUTATION<br/>[FR] COMPOSÉ AYANT UNE ACTIVITÉ INHIBITRICE CONTRE LA MUTATION KRAS G12D
  申请人：TAIHO PHARMACEUTICAL CO LTD

  公开号：WO2021106231A1

  公开（公告）日：2021-06-03

  The present invention relates to a compound having inhibitory activity against KRAS G12D mutation or a salt thereof, and relates to a pharmaceutical composition comprising the compound as an active ingredient.

  本发明涉及一种具有抑制KRAS G12D突变活性或其盐的化合物，并涉及包含该化合物作为活性成分的药物组合物。
• [EN] KRAS INHIBITOR CONJUGATES<br/>[FR] CONJUGUÉS D'INHIBITEURS DE KRAS
  申请人：ERASCA INC

  公开号：WO2022266206A1

  公开（公告）日：2022-12-22

  The present application provides conjugates of protein-binding ligands, in particular G12D mutant KRAS ligands, with ubiquitin ligase ligands and methods for treating diseases such as cancer.

  本申请提供了蛋白质结合配体的共轭物，尤其是G12D突变KRAS配体与泛素连接酶配体，并提供了用于治疗癌症等疾病的方法。
• [EN] ANTICANCER COMPOUNDS<br/>[FR] COMPOSÉS ANTICANCÉREUX
  申请人：UNIV CALIFORNIA

  公开号：WO2022261204A1

  公开（公告）日：2022-12-15

  Disclosed are compounds of formula (I): formula (I) and pharmaceutically acceptable salts thereof. The compounds of the invention are BDII- selective inhibitors of BET proteins, and have therapeutic potential for treating cancer, acute kidney disease, and viral infections, among other diseases.

  本发明涉及以下公式（I）的化合物：公式（I）及其药学上可接受的盐。本发明的化合物是BET蛋白的BDII选择性抑制剂，具有治疗癌症、急性肾脏疾病、病毒感染等疾病的治疗潜力。
• Biphenyl compound or salt thereof
  申请人：TAIHO PHARMACEUTICAL CO., LTD.

  公开号：US10723742B2

  公开（公告）日：2020-07-28

  A compound or a salt thereof represented by Formula (I). An LSD1 inhibitor containing the compound or a salt thereof as an active ingredient. A pharmaceutical composition containing the compound or salt thereof. An antitumor agent containing the compound or a salt thereof as an active ingredient.

  由式（I）代表的化合物或其盐。以该化合物或其盐为活性成分的 LSD1 抑制剂。含有该化合物或其盐的药物组合物。一种含有该化合物或其盐作为活性成分的抗肿瘤剂。